Sight Sciences

SIGHT SCIENCES INC

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Sight Sciences Inc

Health Care

Analyst Ratings

Press Releases

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

General

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Earnings

News

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Sight Sciences to Present at Two Upcoming Investor Conferences

SGHT

BrainsWay Ltd. - American Depositary Shares

BrainsWay

Carlsmed

CeriBell

ClearPoint Neuro

CapsoVision

CVRx

Delcath Systems

Alpha Tau Medical

Electromed

Solana

Inogen

NeuroPace

Nyxoah

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Hldgs

Outset Medical

Owlet

Picard Medical

Senseonics Holdings

Shoulder Innovations

Semler Scientific

SANUWAVE Health

Surmodics

Stereotaxis

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts

USBC

Lake Street

Citigroup

Morgan Stanley

Piper Sandler

Stifel

Comments

Sight Sciences

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO